Opus Genetics and Global RDH12 Alliance announce partnership

(Image credit: ©BillionPhotos.com/AdobeStock)

To strengthen Opus Genetics’ gene therapy program focused on retinol dehydrogenase 12 (RDH12) gene mutations, the company announced its partnership with Global RDH12 Alliance.¹ According to a press release, the Alliance serves as a collaborative platform that unites various inherited retinal disease (IRD) advocacy groups, such as “RDH12 Fund for Sight” in the US and “Eyes on the Future” in the UK.¹

This partnership allows for the continual development of OPGx-RDH12, Opus’ gene therapy program targeting the RDH12 gene mutation for the potential treatment of Leber congenital amaurosis (RDG12-LCA).¹ To deliver a functional copy of the RDH12 gene directly to the retina’s photoreceptors, OPGx-RDH12 uses an adeno-associated virus (AAV) vector.¹

“Preclinical studies in cell and mouse models have shown restoration of RDH12 activity and functional improvements,” Jean Bennett, MD, PhD, Opus Genetics scientific adviser and board of directors member, said in a press release.

Through the partnership, which includes a risk-sharing structure and performance-based milestones, the Alliance will provide up to $1.6 million toward the development of Opus’ OPGx-RDH12 program.¹ The goal of the companies is to file an investigational new drug (IND) application with the US Food and Drug Administration (FDA) by late 2025.

“Since founding the RDH12 Fund for Sight more than a decade ago, our goal has always been to bring a treatment to the RDH12-LCA community,” Mathew Pletcher, PhD, board member of the RDH12 Fund for Sight, said in a press release. Pletcher is also the parent of an adult child living with the condition.

RDH12-LCA affects several thousand people globally. Mutations of the RDH12 gene impair protein function in the retina, which leads to early visual decline by age 2 and rapid progression during the second decade of life.

“This partnership represents a significant step forward. By combining our patient community’s unique, first-hand perspectives on RDH12-LCA and resources with Opus’ gene therapy expertise, we can accelerate the transition of this promising therapy out of the laboratory and into the clinic,” Pletcher said.¹

Reference:

https://fyra.io. Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness - Eyewire+. Eyewire+. Published 2025. Accessed July 28, 2025. https://eyewire.news/news/opus-genetics-and-the-global-rdh12-alliance-partner-to-advance-rdh12-gene-therapy-for-inherited-childhood-blindness?c4src=article:infinite-scroll